Dr. Reddy`s jumps on launching Bortezomib for Injection in US Market
Dr. Reddy’s Laboratories is currently trading at Rs. 4258.00, up by 46.50 points or 1.10% from its previous closing of Rs. 4211.50 on the BSE.
The scrip opened at Rs. 4212.00 and has touched a high and low of Rs. 4265.00 and Rs. 4164.50 respectively. So far 3521 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5,445.00 on 27-Jul-2021 and a 52 week low of Rs. 3,655.00 on 04-Mar-2022.
Last one week high and low of the scrip stood at Rs. 4481.85 and Rs. 4164.50 respectively. The current market cap of the company is Rs. 70,867.13 crore.
Dr. Reddy’s Laboratories has launched Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade (bortezomib) Injection, in the U.S. market approved by the U.S. Food and Drug Administration (USFDA).
The Velcade Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022 according to IQVIA Health. Dr. Reddy’s Bortezomib for Injection, is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
